Report Summary
Eternity Insights can provide a deep dive research report highlighting the market and competitive in-telligence across the key segments of the market. The report also considers the impact of COVID-19 on the global Fragile X Syndrome market. The report considers 2018-2020 historic period, 2021 as base year, and 2022-2028 as forecast period. The report includes quantitative analysis of the market supported by the mar-ket drivers, challenges, and trends to accurately map the market scenario and competition.
Fragile X Syndrome market report is based on robust research methodology designed using blend of research ap-proaches developed using secondary/desk research and validated through the primary research and expert insights. Eternity Insights also uses paid data bases such as FACIVA, Hoovers, and other bench-marking and forecasting tools to provide accurate statistical analysis of supply and demand trends.
To learn more about this report
Key Research Highlights: Market Drivers
The Fragile X Syndrome market is estimated to expand at a considerable growth rate during the forecast period ow-ing to increasing prevalence of venous diseases and increasing new product approvals to cater this demand. Rise in the awareness about the diseases, increasing importance of early diagnosis, and growing spending on chronic diseases are poised to boost the market growth. Moreover, the key players in the market are investing in research and development of technologically advanced products leading to increased utilization of the Fragile X Syndrome products across developed and developing countries of the world.
Key Research Highlights: Market Restrains
Limited awareness about the diseases, high cost of products, low economical condition, and lack of favorable insurance systems restricts the adoption of Fragile X Syndrome products across developing regions of the globe. However, launch of new products with low cost and increasing efforts for market penetration in these regions can offer lucrative growth opportunities for the players in the Fragile X Syndrome market.
To learn more about this report
Key Research Highlights: Trends
Increasing research and development spending on Fragile X Syndrome development has been the leading industry trend of Fragile X Syndrome market
The leading players in the market are focused on developing products which are cost effective and high quality to tap the huge unaddressed opportunities in the developing regions. This can be wit-nessed from the increasing spending on research and development and growing number of new product approvals.
Global Fragile X Syndrome Market Size, 2018-2028 (USD MILLION)
To learn more about this report
Market Segmentation
| Report Attributes |
Details |
| The market size value in 2021 |
USD XX.XX Million |
| CAGR (2021 - 2028) |
XX.XX % |
| The Revenue forecast in 2028 |
USD XX.XX Million |
| Base year for estimation |
2021 |
| Historical data |
2018-2019 |
| Forecast period |
2022-2028 |
| Quantitative units |
- Revenue in USD Million
- CAGR from 2021 to 2028
|
| Report coverage |
Revenue forecast, company ranking, competitive landscape, growth factors, and trends |
| Segments covered |
By Type Outlook, Application Outlook, Regional Outlook |
| By Type Outlook |
ACT-01, AMO-01, ANAVEX-273, AUT-00206, Bryostatin-1, Cannabidiol, Others |
| By Application Outlook |
Clinic, Hopital, Research Center, Other |
| Regional scope |
North America, Europe, Asia Pacific, Latin America, Middle East & Africa |
| Country scope |
U.S., Canada, U.K., Germany, France, BENELUX, China, India, Japan, South Korea, Brazil, Saudi Arabia, UAE, Turkey |
| Key companies profiled |
Aelis Farma SAS, Alcobra Ltd, AMO Pharma Limited, Confluence Pharmaceuticals LLC, Eli Lilly and Company, F. Hoffmann-La Roche Ltd., Marinus Pharmaceuticals, Inc., MI.TO. Technology S.r.L., Neuren Pharmaceuticals Limited, Ovid Therapeutics Inc., Sage Therapeutics, Inc., Zynerba Pharmaceuticals, Inc. |
| Customization Available |
Yes, the report can be tailored to meet your specific requirements. |
Key Market Players
- Aelis Farma SAS
- Alcobra Ltd
- AMO Pharma Limited
- Confluence Pharmaceuticals LLC
- Eli Lilly and Company
- F. Hoffmann-La Roche Ltd.
- Marinus Pharmaceuticals
- Inc.
- MI.TO. Technology S.r.L.
- Neuren Pharmaceuticals Limited
- Ovid Therapeutics Inc.
- Sage Therapeutics
- Inc.
- Zynerba Pharmaceuticals
- Inc.
FRAGILE X SYNDROME Market, By Type
- ACT-01
- AMO-01
- ANAVEX-273
- AUT-00206
- Bryostatin-1
- Cannabidiol
- Others
FRAGILE X SYNDROMEMarket, By Application
- Clinic
- Hopital
- Research Center
- Other
Key Benefits To The Stake Holders
- Qualitative and quantitative analysis of the market based on segmentation involving both economic as well as non-economic factors
- Provision of market value (USD Billion) and volume (Tons) data for each segment and sub-segment
- Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market
- Analysis by geography highlighting the consumption of the product/service in the region as well as indicating the factors that are affecting the market within each region
- Competitive landscape which incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions and acquisitions in the past five years of companies profiled
- Extensive company profiles comprising of company overview, company insights, product benchmarking and SWOT analysis for the major market players
- The current as well as the future market outlook of the industry with respect to recent developments (which involve growth opportunities and drivers as well as challenges and restraints of both emerging as well as developed regions
Table Of Contents
Table of Contents
1 Fragile X Syndrome Market Overview
1.1 Fragile X Syndrome Product Overview
1.2 Fragile X Syndrome Market Segment by Type
1.2.1 ACT-01
1.2.2 AMO-01
1.2.3 ANAVEX-273
1.2.4 AUT-00206
1.2.5 Bryostatin-1
1.2.6 Cannabidiol
1.2.7 Others
1.3 Global Fragile X Syndrome Market Size by Type
1.3.1 Global Fragile X Syndrome Sales and Growth by Type
1.3.2 Global Fragile X Syndrome Sales and Market Share by Type (2013-2018)
1.3.3 Global Fragile X Syndrome Revenue and Market Share by Type (2013-2018)
1.3.4 Global Fragile X Syndrome Price by Type (2013-2018)
2 Global Fragile X Syndrome Market Competition by Company
2.1 Global Fragile X Syndrome Sales and Market Share by Company (2013-2018)
2.2 Global Fragile X Syndrome Revenue and Share by Company (2013-2018)
2.3 Global Fragile X Syndrome Price by Company (2013-2018)
2.4 Global Top Players Fragile X Syndrome Manufacturing Base Distribution, Sales Area, Product Types
2.5 Fragile X Syndrome Market Competitive Situation and Trends
2.5.1 Fragile X Syndrome Market Concentration Rate
2.5.2 Global Fragile X Syndrome Market Share of Top 5 and Top 10 Players
2.5.3 Mergers & Acquisitions, Expansion
3 Fragile X Syndrome Company Profiles and Sales Data
3.1 Aelis Farma SAS
3.1.1 Company Basic Information, Manufacturing Base and Competitors
3.1.2 Fragile X Syndrome Product Category, Application and Specification
3.1.3 Aelis Farma SAS Fragile X Syndrome Sales, Revenue, Price and Gross Margin(2013-2018)
3.1.4 Main Business Overview
3.2 Alcobra Ltd
3.2.1 Company Basic Information, Manufacturing Base and Competitors
3.2.2 Fragile X Syndrome Product Category, Application and Specification
3.2.3 Alcobra Ltd Fragile X Syndrome Sales, Revenue, Price and Gross Margin(2013-2018)
3.2.4 Main Business Overview
3.3 AMO Pharma Limited
3.3.1 Company Basic Information, Manufacturing Base and Competitors
3.3.2 Fragile X Syndrome Product Category, Application and Specification
3.3.3 AMO Pharma Limited Fragile X Syndrome Sales, Revenue, Price and Gross Margin(2013-2018)
3.3.4 Main Business Overview
3.4 Confluence Pharmaceuticals LLC
3.4.1 Company Basic Information, Manufacturing Base and Competitors
3.4.2 Fragile X Syndrome Product Category, Application and Specification
3.4.3 Confluence Pharmaceuticals LLC Fragile X Syndrome Sales, Revenue, Price and Gross Margin(2013-2018)
3.4.4 Main Business Overview
3.5 Eli Lilly and Company
3.5.1 Company Basic Information, Manufacturing Base and Competitors
3.5.2 Fragile X Syndrome Product Category, Application and Specification
3.5.3 Eli Lilly and Company Fragile X Syndrome Sales, Revenue, Price and Gross Margin(2013-2018)
3.5.4 Main Business Overview
3.6 F. Hoffmann-La Roche Ltd.
3.6.1 Company Basic Information, Manufacturing Base and Competitors
3.6.2 Fragile X Syndrome Product Category, Application and Specification
3.6.3 F. Hoffmann-La Roche Ltd. Fragile X Syndrome Sales, Revenue, Price and Gross Margin(2013-2018)
3.6.4 Main Business Overview
3.7 Marinus Pharmaceuticals, Inc.
3.7.1 Company Basic Information, Manufacturing Base and Competitors
3.7.2 Fragile X Syndrome Product Category, Application and Specification
3.7.3 Marinus Pharmaceuticals, Inc. Fragile X Syndrome Sales, Revenue, Price and Gross Margin(2013-2018)
3.7.4 Main Business Overview
3.8 MI.TO. Technology S.r.L.
3.8.1 Company Basic Information, Manufacturing Base and Competitors
3.8.2 Fragile X Syndrome Product Category, Application and Specification
3.8.3 MI.TO. Technology S.r.L. Fragile X Syndrome Sales, Revenue, Price and Gross Margin(2013-2018)
3.8.4 Main Business Overview
3.9 Neuren Pharmaceuticals Limited
3.9.1 Company Basic Information, Manufacturing Base and Competitors
3.9.2 Fragile X Syndrome Product Category, Application and Specification
3.9.3 Neuren Pharmaceuticals Limited Fragile X Syndrome Sales, Revenue, Price and Gross Margin(2013-2018)
3.9.4 Main Business Overview
3.10 Ovid Therapeutics Inc.
3.10.1 Company Basic Information, Manufacturing Base and Competitors
3.10.2 Fragile X Syndrome Product Category, Application and Specification
3.10.3 Ovid Therapeutics Inc. Fragile X Syndrome Sales, Revenue, Price and Gross Margin(2013-2018)
3.10.4 Main Business Overview
3.11 Sage Therapeutics, Inc.
3.12 Zynerba Pharmaceuticals, Inc.
4 Fragile X Syndrome Market Status and Outlook by Regions
4.1 Global Market Status and Outlook by Regions
4.1.1 Global Fragile X Syndrome Market Size and CAGR by Regions
4.1.2 North America
4.1.3 Asia-Pacific
4.1.4 Europe
4.1.5 South America
4.1.6 Middle East and Africa
4.2 Global Fragile X Syndrome Sales and Revenue by Regions
4.2.1 Global Fragile X Syndrome Sales and Market Share by Regions (2013-2018)
4.2.2 Global Fragile X Syndrome Revenue and Market Share by Regions (2013-2018)
4.2.3 Global Fragile X Syndrome Sales, Revenue, Price and Gross Margin (2013-2018)
4.3 North America Fragile X Syndrome Sales, Revenue, Price and Gross Margin
4.3.1 United States
4.3.2 Canada
4.3.3 Mexico
4.4 Europe Fragile X Syndrome Sales, Revenue, Price and Gross Margin
4.4.1 Germany
4.4.2 UK
4.4.3 France
4.4.4 Italy
4.4.5 Russia
4.4.6 Turkey
4.5 Asia-Pacific Fragile X Syndrome Sales, Revenue, Price and Gross Margin
4.5.1 China
4.5.2 Japan
4.5.3 Korea
4.5.4 Southeast Asia
4.5.4.1 Indonesia
4.5.4.2 Thailand
4.5.4.3 Malaysia
4.5.4.4 Philippines
4.5.4.5 Vietnam
4.5.5 India
4.5.6 Australia
4.6 South America Fragile X Syndrome Sales, Revenue, Price and Gross Margin
4.6.1 Brazil
4.7 Middle East and Africa Fragile X Syndrome Sales, Revenue, Price and Gross Margin
4.7.1 Egypt
4.7.2 GCC Countries
5 Fragile X Syndrome Application/End Users
5.1 Fragile X Syndrome Segment by Application
5.1.1 Clinic
5.1.2 Hopital
5.1.3 Research Center
5.2 Global Fragile X Syndrome Product Segment by Application
5.2.1 Global Fragile X Syndrome Sales by Application
5.2.2 Global Fragile X Syndrome Sales and Market Share by Application (2013-2018)
6 Global Fragile X Syndrome Market Forecast
6.1 Global Fragile X Syndrome Sales, Revenue Forecast (2018-2025)
6.1.1 Global Fragile X Syndrome Sales and Growth Rate Forecast (2018-2025)
6.1.1 Global Fragile X Syndrome Revenue and Growth Rate Forecast (2018-2025)
6.2 Global Fragile X Syndrome Forecast by Regions
6.2.1 North America Fragile X Syndrome Sales and Revenue Forecast (2018-2025)
6.2.2 Europe Fragile X Syndrome Sales and Revenue Forecast (2018-2025)
6.2.3 Asia-Pacific Fragile X Syndrome Sales and Revenue Forecast (2018-2025)
6.2.3.1 China
6.2.3.2 Japan
6.2.3.3 Korea
6.2.3.4 Southeast Asia
6.2.3.5 India
6.2.3.6 Australia
6.2.4 South America Fragile X Syndrome Sales and Revenue Forecast (2018-2025)
6.2.5 Middle East and Africa Fragile X Syndrome Sales and Revenue Forecast (2018-2025)
6.2.5.1 Egypt
6.2.5.2 GCC Countries
6.3 Fragile X Syndrome Forecast by Type
6.3.1 Global Fragile X Syndrome Sales and Revenue Forecast by Type (2018-2025)
6.3.2 ACT-01 Gowth Forecast
6.3.3 AMO-01 Gowth Forecast
6.4 Fragile X Syndrome Forecast by Application
6.4.1 Global Fragile X Syndrome Sales Forecast by Application (2018-2025)
6.4.2 Global Fragile X Syndrome Forecast in Clinic
6.4.3 Global Fragile X Syndrome Forecast in Hopital
7 Fragile X Syndrome Upstream Raw Materials
7.1 Fragile X Syndrome Key Raw Materials
7.1.1 Key Raw Materials
7.1.2 Key Raw Materials Price
7.1.3 Raw Materials Key Suppliers
7.2 Manufacturing Cost Structure
7.2.1 Raw Materials
7.2.2 Labor Cost
7.2.3 Manufacturing Expenses
7.3 Fragile X Syndrome Industrial Chain Analysis
8 Marketing Strategy Analysis, Distributors
8.1 Marketing Channel
8.1.1 Direct Marketing
8.1.2 Indirect Marketing
8.1.3 Marketing Channel Development Trend
8.2 Distributors
8.3 Downstream Customers
9 Research Findings and Conclusion
Appendix
Methodology/Research Approach
Research Programs/Design
Market Size Estimation
Market Breakdown and Data Triangulation
Data Source
Secondary Sources
Primary Sources
Disclaimer
